Research Article
Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect
Table 1
Demographic and ocular data characterized by the responder type.
| | Variable | Overall
N = 2361 | Nonresponder
N = 401 | Initial responder
N = 651 | Long-term responder
N = 731 | Robust long-term responder
N = 411 | Super responder
N = 171 | value2 |
| | Demographics | | | | | | | | | Female sex, N (%) | 125 (53) | 20 (50) | 35 (54) | 40 (55) | 24 (59) | 6 (35) | 0.57 | | Age | | | | | | | 0.38 | | Mean ± SD | 71.6 ± 14.2 | 73.2 ± 13.1 | 72.6 ± 15.4 | 69.8 ± 12.8 | 72.7 ± 15.0 | 69.0 ± 16.7 | | | Range | 10–98 | 43–98 | 10–97 | 30–91 | 31–95 | 31–88 | | | Ethnicity, N (%) | | | | | | | | | White | 165 (70) | 25 (62) | 49 (75) | 51 (70) | 27 (66) | 13 (76) | 0.36 | | Black | 23 (9.7) | 6 (15) | 6 (9.2) | 9 (12) | 2 (4.9) | | | | Asian | 16 (6.8) | 3 (7.5) | 4 (6.2) | 3 (4.1) | 3 (7.3) | 3 (18) | | | Hispanic | 7 (3.0) | 2 (5.0) | | 3 (4.1) | 1 (2.4) | 1 (5.9) | | | Other | 25 (10.6) | 4 (10) | 6 (9.2) | 7 (9.6) | 8 (20) | | | | Glaucoma stage, N (%) | | | | | | | 0.024 | | Indeterminate | 19 (8.0) | | 3 (4.6) | 10 (14) | 2 (4.9) | 4 (24) | | | Mild | 31 (13) | 8 (20) | 6 (9.2) | 10 (14) | 5 (12) | 2 (12) | | | Moderate | 55 (23) | 8 (20) | 18 (28) | 21 (29) | 5 (12) | 2 (12) | | | Severe | 132 (56) | 24 (60) | 38 (58) | 32 (44) | 29 (71) | 9 (53) | | | Glaucoma type, N (%) | | | | | | | 0.60 | | Primary open-angle | 150 (64) | 28 (70) | 42 (65) | 48 (66) | 24 (59) | 8 (47) | | | Pseudoexfoliative | 28 (12) | 5 (12) | 9 (14) | 8 (11) | 3 (7.3) | 3 (18) | | | Mixed mechanism | 20 (8.5) | 2 (5.0) | 6 (9.2) | 5 (6.8) | 5 (12) | 2 (12) | | | Normal tension | 11 (4.7) | 1 (2.5) | 2 (3.1) | 4 (5.5) | 4 (9.8) | | | | Chronic angle-closure | 10 (4.2) | 3 (7.5) | 3 (4.6) | 1 (1.4) | 2 (4.9) | 1 (5.9) | | | Pigmentary | 4 (1.7) | 1 (2.5) | | 2 (2.7) | | 1 (5.9) | | | Uveitic | 3 (1.3) | | | 2 (2.7) | 1 (2.4) | | | | Ocular hypertension | 3 (1.3) | | | 1 (1.4) | 1 (2.4) | 1 (5.9) | | | Aphakic | 2 (0.8) | | | 1 (1.4) | | 1 (5.9) | | | Congenital | 2 (0.8) | | 1 (1.5) | 1 (1.4) | | | | | Steroid | 2 (0.8) | | 2 (3.1) | | | | | | Neovascular | 1 (0.4) | | | | 1 (2.4) | | | | Prior surgery | 105 (44) | 20 | 30 | 28 | 17 | 10 | 0.84 | | Phaco | 89 (85) | 18 (90) | 24 (80) | 25 (89) | 13 (76) | 9 (90) | | | Trabeculectomy | 11 (10) | 1 (5.0) | 5 (17) | 2 (7.1) | 2 (12) | 1 (10) | | | Tube shunt | 3 (2.9) | 1 (5.0) | | 1 (3.6) | 1 (5.9) | | | | MIGS | 2 (1.9) | | 1 (3.3) | | 1 (5.9) | | | | Prior laser | 84 | 16 | 29 | 20 | 12 | 7 | 0.16 | | Laser trabeculoplasty | 61 (73) | 11 (69) | 18 (62) | 16 (80) | 11 (92) | 5 (71) | | | CPC/ECP | 15 (18) | 3 (19) | 10 (34) | 1 (5.0) | | 1 (14) | | | Iridotomy | 8 (9.5) | 2 (12) | 1 (3.4) | 3 (15) | 1 (8.3) | 1 (14) | | | Number of agents, N (%) | | | | | | | 0.74 | | 2nd agent | 20 (8.5) | 3 (7.5) | 6 (9.2) | 7 (9.6) | 4 (9.8) | | | | 3rd agent | 41 (17) | 7 (18) | 10 (15) | 14 (19) | 7 (17) | 3 (18) | | | 4th agent | 78 (33) | 10 (25) | 20 (31) | 24 (33) | 17 (41) | 7 (41) | | | 5th agent | 77 (33) | 18 (45) | 23 (35) | 23 (32) | 7 (17) | 6 (35) | | | 6th+ agent | 20 (8.5) | 2 (5.0) | 6 (9.2) | 5 (6.8) | 6 (15) | 1 (5.9) | | | Baseline IOP (mmHg) | | | | | | | | | Mean ± SD | 18.2 ± 5.2 | 17.2 ± 3.7 | 17.3 ± 4.9 | 18.1 ± 4.8 | 17.1 ± 3.4 | 26.8 ± 7.1 | <0.001 | | IOP category, N (%) | | | | | | | <0.001 | | Low (IOP < 15) | 55 (23) | 12 (30) | 18 (28) | 16 (22) | 9 (22) | | | | Medium (15 ≤ IOP < 20) | 108 (46) | 17 (42) | 31 (48) | 33 (45) | 26 (63) | 1 (5.9) | | | High (20 ≤ IOP < 25) | 47 (20) | 10 (25) | 10 (15) | 15 (21) | 5 (12) | 7 (41) | | | Very high (IOP ≥ 25) | 26 (11) | 1 (2.5) | 6 (9.2) | 9 (12) | 1 (2.4) | 9 (53) | |
|
|
SD = standard deviation; IOP = intraocular pressure; phaco = cataract surgery; MIGS = microinvasive glaucoma surgery; CPC/ECP = diode cyclophotocoagulation/endoscopic cyclophotocoagulation. 1mean (SD); (min-max); median for numerical variables; (% missing), or frequency (%); (% missing) for categorical variables. 2Kruskal–Wallis rank-sum test. Pearson’s Chi-squared test.
|
